A carregar...
NCMP-02. MYASTHENIA GRAVIS INDUCED BY AVELUMAB
Monoclonal antibodies targeting PD- 1 (nivolumab and pembrolizumab) and PD-L1 (avelumab, atezolizumab, and durvalumab) are FDA approved for the treatment of metastatic cancers. Immune-related adverse events (irAEs) are autoimmune diseases which occur following treatment with PD-1 and PD-L1 inhibitor...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6847032/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.748 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|